PROGRAM LEADERS--VIRAL AND MOLECULAR

项目负责人——病毒和分子

• 批准号: 8180927
• 负责人: JANET S BUTEL
• 金额: $ 1.74万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-17 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8180927
• 关键词: Acquired Immunodeficiency Syndrome; Address; Area; Basic Science; Cancer Center; Chromosomes, Human, Pair 1; Clinical Trials; Collaborations; Development; Doctor of Philosophy; Funding; Goals; Grant; Human; Joints; Journals; Malignant Neoplasms; Manuscripts; Medicine; Mitotic Chromosome; Molecular; Molecular Carcinogenesis; National Cancer Institute; Oncogenic; Peer Review; Peer Review Grants; Process; Program Reviews; Publishing; Regulation; Research; Research Personnel; Signal Transduction; System; Translational Research; Viral; Work; anticancer research; base; college; fundamental research; improved; inhibitor/antagonist; innovation; member; novel; programs; synergism; tumorigenesis; virology

The Viral and Molecular Oncogenesis (VMO) Research Program consists of investigators who are conducting fundamental research on the molecular basis of cancer development. The program has three thematic areas: (1) Chromosomes and mitotic regulation, (2) Oncogenic signaling, and (3) Viral oncogenesis. The program consists of 36 primary members from 10 academic departments; 27 of 28 (96%) of the research members are funded. Peer-reviewed grant funds total nearly $16.0 million annually, with $3.8 million from the National Cancer Institute. Twenty-nine secondary members also participate in the VMO Program. Since its initial review, the program has built on its strengths and improved in areas of weakness. The program was reorganized around themes that better reflect member strengths, encouraged new collaborations by targeted use of pilot grant funds, and organized joint retreats. Members of the program published 187 cancer-related manuscripts in peer-reviewed journals; of these 20% represented intraprogrammatic collaborations (an increase from 3%) and 31% were interprogrammatic. Translational research efforts saw a novel Stat3 inhibitor moving toward clinical trial. A new initiative in the area of HIV-associated malignancies has been undertaken; it draws on our strengths in virology, addresses an emerging area of need, has translational opportunities, and involves a collaboration between the Cancer Center and the Center for AIDS Research. The program leaders are Janet S. Butel, Ph.D. and William R. Brinkley, Ph.D.

病毒和分子肿瘤发生（VMO）研究计划由研究人员组成，他们正在对癌症发展的分子基础进行基础研究。该计划有三个主题领域：（1）染色体和有丝分裂调控，（2）致癌信号，（3）病毒致癌。 该计划由来自10个学术部门的36名主要成员组成; 28名研究成员中有27名（96%）获得资助。同行评审的赠款资金总额每年近1600万美元，其中380万美元来自国家癌症研究所。29个二级成员也参加了VMO方案。自初步审查以来，该方案在其优势的基础上进行了改进，并在薄弱领域进行了改进。 该计划围绕更好地反映成员优势的主题进行了重组，通过有针对性地使用试点赠款基金鼓励新的合作，并组织了联合务虚会。该计划的成员在同行评审期刊上发表了187篇与癌症相关的手稿;其中20%代表了计划内合作（从3%增加），31%是跨计划的。转化研究的努力看到了一种新型的Stat 3抑制剂走向临床试验。在艾滋病毒相关的恶性肿瘤领域的一项新举措已经进行;它借鉴了我们在病毒学的优势，解决了一个新兴的需求领域，有转化的机会，并涉及癌症中心和艾滋病研究中心之间的合作。项目负责人是珍妮特·S。Butel博士和William R. Brinkley博士